XT
VYNE icon

XTX Topco’s VYNE Therapeutics VYNE Stock Holding History

XTX Topco’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.6K Buy
158,396
+79,356
+100% +$46.3K ﹤0.01% 3119
2025
Q4 		$45.9K Buy
+79,040
New +$31.7K ﹤0.01% 2858
2025
Q3 		– Sell
-56,908
Closed -$93.9K – 3357
2025
Q2 		$93.9K Buy
56,908
+23,856
+72% +$31K ﹤0.01% 1896
2025
Q1 		$52.2K Buy
33,052
+12,034
+57% +$29.6K ﹤0.01% 1996
2024
Q4 		$70.4K Buy
+21,018
New +$55K 0.01% 1836
2022
Q1 		– Sell
-947
Closed -$17K – 975
2021
Q4 		$17K Buy
+947
New +$20.3K 0.01% 633

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

XTX Topco's VYNE Position: Q1 2026 in Review

XTX Topco increased its VYNE Therapeutics (VYNE) stake by 100% in Q1 2026, buying an estimated $46.3K and bringing the position to 158,396 shares worth $94.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

XTX Topco first reported a position in VYNE in Q4 2021 and has held it in 6 quarters since. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • XTX Topco held 158,396 shares of VYNE Therapeutics worth $94.6K as of Q1 2026.
  • XTX Topco bought 79,356 VYNE Therapeutics shares in Q1 2026, an estimated $46.3K.
  • VYNE Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3119 holding.
  • XTX Topco first reported a position in VYNE Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.